MCID: LRY018
MIFTS: 47

Laryngeal Squamous Cell Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma 12 54 15 17
Squamous Cell Carcinoma of Head and Neck 44
Epidermoid Carcinoma of the Larynx 12
Squamous Cell Carcinoma of Larynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2876
MeSH 44 D000077195
NCIt 50 C4044
SNOMED-CT 67 707358000
UMLS 70 C0280324

Summaries for Laryngeal Squamous Cell Carcinoma

Disease Ontology : 12 A laryngeal carcinoma that has material basis in squamous cells.

MalaCards based summary : Laryngeal Squamous Cell Carcinoma, also known as squamous cell carcinoma of head and neck, is related to larynx cancer and papilloma. An important gene associated with Laryngeal Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs mometasone furoate and Titanium dioxide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and thyroid, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Laryngeal Squamous Cell Carcinoma

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 larynx cancer 32.5 TP53 TERT NME1 MIR21 EGFR CDKN2A
2 papilloma 31.7 TP53 EGFR CDKN2A CCND1
3 squamous cell papilloma 31.7 TP53 CDKN2A
4 squamous cell carcinoma 31.5 TP53 NME1 NEAT1 MALAT1 HOTAIR H19
5 in situ carcinoma 31.0 TP53 EGFR CDKN2A CDH1 CCND1
6 b-cell lymphoma 31.0 TP53 MIR21 MALAT1 HOTAIR CDKN2A CCND1
7 suppression of tumorigenicity 12 31.0 TP53 EGFR CDKN2A CDH1
8 human papillomavirus infectious disease 31.0 TP53 TERT CDKN2A
9 gastroesophageal reflux 30.9 TP53 TERT EGFR CCND1
10 oral cancer 30.9 TP53 MIR21 EGFR CDKN2A CDH1 CCND1
11 oropharynx cancer 30.8 TP53 EGFR CDKN2A CDH1 CCND1
12 basaloid squamous cell carcinoma 30.7 TP53 EGFR CDKN2A
13 adenocarcinoma 30.7 TP53 MALAT1 H19 EGFR CDKN2A CDH1
14 verrucous carcinoma 30.7 TP53 EGFR CDKN2A CCND1
15 laryngeal disease 30.7 TP53 MIR21 CDKN2A CCND1
16 squamous cell carcinoma, head and neck 30.6 TP53 MIR21 HOTAIR H19 EGFR CDKN2A
17 small cell carcinoma 30.6 TP53 EGFR CDKN2A
18 suppressor of tumorigenicity 3 30.6 TP53 CDKN2A
19 adenoid cystic carcinoma 30.5 TP53 EGFR CDKN2A CDH1 CCND1
20 thyroid cancer, nonmedullary, 1 30.5 NEAT1 MALAT1 HOTAIR H19
21 retinitis pigmentosa 11 30.5 TP53 NEAT1 HOTAIR EGFR CDKN2A
22 retinoblastoma 30.5 TP53 MALAT1 HOTAIR CDKN2A CCND1 CCAT1
23 gastrointestinal stromal tumor 30.5 TP53 HOTAIR EGFR CDKN2A CDH1 CCND1
24 intrahepatic cholangiocarcinoma 30.4 TP53 EGFR CDH1 CCND1 CCAT1
25 thyroid carcinoma 30.4 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
26 leukemia, chronic myeloid 30.3 TP53 NME1 HOTAIR H19 EGFR
27 lung cancer susceptibility 3 29.9 TP53 TERT MIR21 MALAT1 HOTAIR H19
28 cholangiocarcinoma 29.8 TP53 TERT NEAT1 MIR21 MALAT1 H19
29 melanoma 29.7 TP53 TERT NME1 MALAT1 HOTAIR H19
30 renal cell carcinoma, nonpapillary 29.7 TP53 NME1 MIR21 MALAT1 HOTAIR H19
31 bladder cancer 29.6 TP53 TERT MIR21 MALAT1 HOTAIR H19
32 oral squamous cell carcinoma 29.4 TP53 NEAT1 MIR21 MALAT1 HOTAIR H19
33 osteogenic sarcoma 29.3 TP53 NEAT1 MALAT1 HOXA11-AS HOTAIR H19
34 nasopharyngeal carcinoma 29.0 TP53 TERT NME1 NEAT1 MIR21 MALAT1
35 lung cancer 28.5 TP53 TERT NME1 NEAT1 MIR21 MALAT1
36 leukoplakia 10.6
37 esophageal leukoplakia 10.5 TP53 CCND1
38 pancreatic foamy gland adenocarcinoma 10.5 TP53 CCND1
39 nodular malignant melanoma 10.5 TP53 CDKN2A CCND1
40 mammary analogue secretory carcinoma 10.5 TP53 EGFR CCND1
41 vulvar intraepithelial neoplasia 10.5 TP53 CDKN2A CDH1
42 synchronous bilateral breast carcinoma 10.5 TP53 EGFR CCND1
43 malignant peritoneal mesothelioma 10.5 EGFR CDKN2A
44 childhood malignant schwannoma 10.5 TP53 CCND1 AURKA
45 supraglottis cancer 10.5 TP53 EGFR CDKN2A
46 ovarian seromucinous carcinoma 10.5 TP53 CDKN2A
47 adult malignant schwannoma 10.5 TP53 CDKN2A AURKA
48 epstein-barr virus-associated gastric carcinoma 10.5 CDKN2A CDH1
49 sarcomatoid transitional cell carcinoma 10.5 TP53 CDH1
50 47,xyy 10.5

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:



Diseases related to Laryngeal Squamous Cell Carcinoma

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.66 AURKA EGFR
2 Decreased viability GR00055-A-2 9.66 AURKA EGFR
3 Decreased viability GR00221-A-1 9.66 AURKA CDH1 CDKN2A EGFR NME1
4 Decreased viability GR00221-A-2 9.66 AURKA NME1
5 Decreased viability GR00221-A-3 9.66 CDKN2A
6 Decreased viability GR00221-A-4 9.66 AURKA CDKN2A EGFR
7 Decreased viability GR00231-A 9.66 AURKA
8 Decreased viability GR00249-S 9.66 AURKA NME1
9 Decreased viability GR00301-A 9.66 CDH1
10 Decreased viability GR00402-S-2 9.66 AURKA CDH1 NME1

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 AURKA CCND1 CDH1 CDKN2A EGFR NME1

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Titanium dioxide Approved Phase 4 13463-67-7
3
Petrolatum Approved, Investigational Phase 4 8009-03-8
4
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
5
Fluorouracil Approved Phase 4 51-21-8 3385
6
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
7 Anti-Allergic Agents Phase 4
8 Antimetabolites Phase 4
9 Immunosuppressive Agents Phase 4
10 Immunologic Factors Phase 4
11 Antibiotics, Antitubercular Phase 4
12 Anti-Bacterial Agents Phase 4
13 Alkylating Agents Phase 4
14 Mitomycins Phase 4
15
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
16
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
17
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
18
Dapsone Approved, Investigational Phase 3 80-08-0 2955
19
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
20
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
21
Lenvatinib Approved, Investigational Phase 3 417716-92-8
22
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
23
Pentetic acid Approved Phase 3 67-43-6
24
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
25
Zalutumumab Investigational Phase 3 667901-13-5, 828933-61-3
26
Tirapazamine Investigational Phase 3 27314-97-2
27
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
28
Tremelimumab Investigational Phase 3 745013-59-6
29
Nimorazole Investigational Phase 3 6506-37-2
30 Anesthetics Phase 3
31 Endostatins Phase 3 71581480
32
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
33 Antimalarials Phase 3
34 Immunoglobulin G Phase 3
35 Lugol's solution Phase 3
36 Pharmaceutical Solutions Phase 3
37 Antirheumatic Agents Phase 3
38 Radiopharmaceuticals Phase 3
39 Antiparasitic Agents Phase 3
40 Antiprotozoal Agents Phase 3
41 Chelating Agents Phase 3
42 Anticoagulants Phase 3
43 Technetium Tc 99m Pentetate Phase 3
44 Plasma Substitutes Phase 3
45 Dextrans Phase 3
46 Blood Substitutes Phase 3
47 Orange Approved Phase 2
48
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
50
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141

Interventional clinical trials:

(show top 50) (show all 729)
# Name Status NCT ID Phase Drugs
1 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
2 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
3 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
4 A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor Recruiting NCT04766827 Phase 4 albumin-bound paclitaxel
5 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). Recruiting NCT04489888 Phase 4 Pembrolizumab;Carboplatin;Paclitaxel
6 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
7 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
8 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Unknown status NCT02661152 Phase 3 Nimorazole
9 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
10 Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb) Completed NCT02715596 Phase 3
11 A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck Completed NCT00206219 Phase 3 Gefitinib;methotrexate
12 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
13 Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy Completed NCT02347332 Phase 3 Vinflunine;Methotrexate
14 Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study. Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
15 Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
16 DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Completed NCT00496652 Phase 3 Zalutumumab
17 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
18 Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
19 Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
20 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
21 Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Asian Subjects Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
22 Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux Completed NCT00609284 Phase 3 cetuximab;Carboplatin, 5FU concomitant
23 A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Completed NCT01950689 Phase 3 Nimorazole
24 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT03349710 Phase 3 Cetuximab;Cisplatin
25 Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
26 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
27 An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck Completed NCT00995293 Phase 3 DOCETAXEL;CISPLATIN;5-FLUOROURACIL
28 Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation Completed NCT00771641 Phase 3
29 A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck Recruiting NCT03576417 Phase 3 Cisplatin;Nivolumab
30 Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma Recruiting NCT03519048 Phase 3
31 Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) Recruiting NCT03855384 Phase 3 TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
32 A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Recruiting NCT03815903 Phase 3 Induction chemotherapy
33 A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT04428333 Phase 3 feladilimab;Pembrolizumab;Placebo;Platinum based chemotherapy;Fluorouracil (5FU)
34 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) Recruiting NCT03765918 Phase 3 Cisplatin 100 mg/m^2
35 A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) Recruiting NCT04459715 Phase 3 Debio 1143;Cisplatin;Placebo
36 Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial Recruiting NCT02923258 Phase 2, Phase 3 Docetaxel;Cisplatinum
37 Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin Recruiting NCT03340896 Phase 3 Docetaxel;Cisplatin;Fluorouracil
38 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
39 Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer Recruiting NCT00957086 Phase 3 Nimotuzumab;Placebo
40 A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010). Recruiting NCT04199104 Phase 3 Lenvatinib;Pembrolizumab;Placebo
41 A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT04128696 Phase 3 feladilimab;Pembrolizumab;Placebo
42 A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor Recruiting NCT04590963 Phase 3 Monalizumab;Cetuximab
43 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03452137 Phase 3 Atezolizumab;Placebo
44 SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial Recruiting NCT04146402 Phase 3 SCT-I10A+chemo;Placebos+chemo
45 A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT02383966 Phase 3 Cetuximab;Cisplatin/Carboplatin;5-fluorouracil
46 A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412) Active, not recruiting NCT03040999 Phase 3 Placebo;Cisplatin
47 Concurrent Hypofractionated Radiotherapy With Weekly Cisplatin in Locally Advanced Squamous Cell Carcinoma Head and Neck SCCHN Active, not recruiting NCT03880396 Phase 2, Phase 3
48 An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02741570 Phase 3 Cetuximab/Erbitux;Cisplatin/Platinol;Carboplatin/Paraplatin;Fluorouracil/Adrucil
49 A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting NCT03358472 Phase 3 Pembrolizumab;Epacadostat;Cetuximab;Cisplatin;Carboplatin;5-Fluorouracil
50 Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT01864850 Phase 3

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Cochrane evidence based reviews: squamous cell carcinoma of head and neck

Genetic Tests for Laryngeal Squamous Cell Carcinoma

Anatomical Context for Laryngeal Squamous Cell Carcinoma

MalaCards organs/tissues related to Laryngeal Squamous Cell Carcinoma:

40
Lymph Node, T Cells, Thyroid, Skin, Endothelial, Neutrophil, Liver

Publications for Laryngeal Squamous Cell Carcinoma

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 2171)
# Title Authors PMID Year
1
GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. 61 54
19922706 2010
2
Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. 54 61
19741544 2010
3
EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. 61 54
19789511 2009
4
Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. 54 61
19669840 2009
5
Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. 61 54
19375219 2009
6
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. 54 61
19813623 2009
7
[The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma]. 61 54
19670620 2009
8
Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 61 54
19148533 2009
9
[The expression of Galectin-3 and VEGF in laryngeal squamous cell carcinoma]. 54 61
19452726 2009
10
Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. 54 61
19183379 2009
11
p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. 61 54
18607952 2009
12
[hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice]. 54 61
19173799 2008
13
Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. 54 61
18998509 2008
14
[Study of the lymph node micrometastasis in patients with supraglottic carcinoma]. 54 61
19166031 2008
15
Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. 61 54
18602381 2008
16
[Effect of CDK2 on proliferation in laryngeal squamous cell carcinoma]. 61 54
19166026 2008
17
[Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma]. 54 61
19086654 2008
18
[Detection of Skp2 mRNA gene expression using fluorogenic probe quantitative RT-PCR method in laryngeal squamous cell carcinoma]. 54 61
18800682 2008
19
Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. 54 61
18509272 2008
20
Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. 54 61
17592663 2008
21
Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. 61 54
18357366 2008
22
[Expression of cyclin G1 in laryngeal squamous cell carcinoma and its clinicopathologic significance]. 54 61
18788592 2008
23
[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. 54 61
18476631 2008
24
Possible prognostic role of p53 expression in laryngeal squamous cell carcinoma of non-smokers, non-alcoholic patients. 54 61
18607961 2008
25
Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. 61 54
18787961 2008
26
Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. 61 54
17475427 2007
27
Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. 61 54
17974987 2007
28
[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]. 61 54
18307884 2007
29
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. 54 61
17712678 2007
30
[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]. 61 54
18051571 2007
31
[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. 61 54
17634026 2007
32
[Clinical significance and expression of FLIP and PTEN protein in laryngeal squamous cell carcinoma]. 61 54
17441421 2007
33
Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). 61 54
17328665 2007
34
The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. 61 54
17264532 2007
35
[Expression and clinical significance of matrix metalloproteinase-2 in laryngeal squamous cell carcinoma]. 61 54
17357514 2006
36
5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. 61 54
17207318 2006
37
[Expression of telomerase reverse transcriptase and its relationship with expression of c-myc in laryngeal squamous cell carcinomas]. 61 54
17219990 2006
38
Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. 61 54
16938565 2006
39
Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. 54 61
17094406 2006
40
Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. 61 54
16832409 2006
41
[The investigation of STK15 gene amplification and overexpression in laryngeal squamous cell carcinoma]. 54 61
16767676 2006
42
[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF]. 54 61
16845966 2006
43
[The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma]. 54 61
16739377 2006
44
[The clinical significance of the expression of p63 gene in laryngeal squamous cell carcinoma]. 61 54
16646404 2006
45
Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. 61 54
16265652 2006
46
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance. 61 54
16711020 2006
47
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. 61 54
15965904 2006
48
[Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. 61 54
16405742 2006
49
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]. 54 61
16763427 2006
50
Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. 61 54
16711019 2006

Variations for Laryngeal Squamous Cell Carcinoma

Expression for Laryngeal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.

Pathways for Laryngeal Squamous Cell Carcinoma

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 TP53 EGFR CDKN2A CDH1 CCND1
2 12.57 TP53 TERT EGFR CDKN2A CDH1 CCND1
3
Show member pathways
12.48 TP53 EGFR CDKN2A CDH1 CCND1
4
Show member pathways
12.4 TP53 TERT EGFR CDKN2A CDH1 CCND1
5 12.32 TP53 MIR21 EGFR CDKN2A CCND1
6 12.2 TP53 CDKN2A CDH1 CCND1
7 12.17 TP53 TERT CDKN2A CCND1
8 12.11 TP53 MIR21 EGFR CCND1
9 11.98 TP53 EGFR CDH1 CCND1
10 11.74 TP53 EGFR CDH1 CCND1 AURKA
11 11.67 TP53 EGFR CDKN2A CCND1
12 11.64 TP53 TERT NME1
13 11.62 TERT CDH1 CCND1
14 11.51 TERT EGFR CCND1
15 11.1 NME1 CDH1 CCND1
16 10.96 TP53 EGFR CDKN2A CCND1
17 10.88 TP53 EGFR CDKN2A CDH1 CCND1
18 10.65 TP53 HOTAIR

GO Terms for Laryngeal Squamous Cell Carcinoma

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 TP53 TERT MIR21 EGFR AURKA
2 positive regulation of inflammatory response GO:0050729 9.71 NEAT1 MIR21 EGFR
3 regulation of protein stability GO:0031647 9.69 TERT CDKN2A AURKA
4 cellular response to drug GO:0035690 9.61 TP53 NME1 EGFR
5 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.58 TERT EGFR CCND1
6 cellular response to virus GO:0098586 9.54 RRP1B MIR21 H19
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.49 TP53 EGFR
8 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.48 TP53 TERT
9 mitotic G1 DNA damage checkpoint GO:0031571 9.46 TP53 CCND1
10 liver regeneration GO:0097421 9.33 EGFR CCND1 AURKA
11 negative regulation of superoxide dismutase activity GO:1901670 9.32 MIR21 H19
12 response to UV-A GO:0070141 9.26 EGFR CCND1
13 negative regulation of gene expression GO:0010629 9.17 TP53 TERT NME1 MIR21 HOXA11-AS CDKN2B-AS1
14 replicative senescence GO:0090399 9.13 TP53 TERT CDKN2A

Molecular functions related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.35 TP53 EGFR CDKN2A CCND1 AURKA
2 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A

Sources for Laryngeal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....